Go Pro
NASDAQ:PCLA

PicoCELA (PCLA) Stock Price, News & Analysis

PicoCELA logo
$4.87 -0.17 (-3.37%)
Closing price 08/4/2026 03:59 PM Eastern
Extended Trading
$5.82 +0.96 (+19.61%)
As of 07:04 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About PicoCELA Stock (NASDAQ:PCLA)

Advanced

Key Stats

Today's Range
$4.81
$5.02
50-Day Range
$3.07
$9.89
52-Week Range
$1.35
$16.80
Volume
28,016 shs
Average Volume
299,503 shs
Market Capitalization
$194.80 thousand
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Sell

Company Overview

PicoCELA, Inc. is a clinical-stage biotechnology company focused on the development of next-generation vaccines and immunotherapies based on its proprietary self-assembling protein nanoparticle platform. The company engineers functionalized, virus-like protein particles designed to present disease-relevant antigens in their native conformation, with the goal of eliciting potent B-cell and T-cell responses. PicoCELA’s platform enables the rapid design and production of vaccine candidates against infectious diseases as well as antigen-specific immunotherapies for certain cancers.

The company’s pipeline includes vaccine programs targeting SARS-CoV-2 and other respiratory pathogens, leveraging its nanoparticle scaffolds to display full-length viral spike proteins or other key antigens. Preclinical studies have demonstrated robust neutralizing antibody titers and T-cell activation in animal models, supporting progression toward clinical trials. Beyond infectious disease, PicoCELA is exploring oncology applications in which tumor-associated antigens are presented on its nanoscaffold to stimulate a targeted immune attack against cancer cells.

Founded in 2019 and headquartered in Connecticut, PicoCELA went public via a Nasdaq listing in 2021. The company collaborates with academic research centers and contract development organizations across the United States to advance its preclinical and future clinical-stage programs. PicoCELA’s leadership team comprises experienced executives and scientific founders with backgrounds in immunology, protein engineering and vaccine development, positioning the company to address unmet medical needs through its modular nanoparticle technology.

AI Generated. May Contain Errors.

PicoCELA Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
5th Percentile Overall Score

PCLA MarketRank™: 

PicoCELA scored higher than 5% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    PicoCELA has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    PicoCELA has only been the subject of 1 research reports in the past 90 days.

  • Read more about PicoCELA's stock forecast and price target.
  • Price to Book Value per Share Ratio

    PicoCELA has a P/B Ratio of 0.06. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    504.45% of the float of PicoCELA has been sold short.
  • Short Interest Ratio / Days to Cover

    PicoCELA has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in PicoCELA has recently increased by 77.21%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    PicoCELA does not currently pay a dividend.

  • Dividend Growth

    PicoCELA does not have a long track record of dividend growth.

  • News Coverage This Week

    MarketBeat has tracked 1 news article for PicoCELA this week, compared to 1 article on an average week.
  • Search Interest

    Only 1 people have searched for PCLA on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added PicoCELA to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, PicoCELA insiders have not sold or bought any company stock.

  • Percentage Held by Institutions

    PicoCELA has minimal institutional ownership at this time.

  • Read more about PicoCELA's insider trading history.
Receive PCLA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PicoCELA and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

PCLA Stock News Headlines

Picocela ADR (PCLA)
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.tc pixel
Picocela ADR (PCLA) Stock Split History
See More Headlines

PCLA Stock Analysis - Frequently Asked Questions

PicoCELA's stock was trading at $9.06 at the start of the year. Since then, PCLA shares have decreased by 46.2% and is now trading at $4.87.

PicoCELA's stock reverse split before market open on Monday, January 26th 2026.A 1-30 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Sunday, January 25th 2026. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

PicoCELA (PCLA) raised $10 million in an initial public offering on Wednesday, January 15th 2025. The company issued 2,000,000 shares at a price of $4.00-$6.00 per share. Benjamin Securities and Prime Number Capital served as the underwriters for the IPO.

Shares of PCLA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Today
8/04/2026
Fiscal Year End
9/30/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Communications Equipment
Sub-Industry
Communications Equipment
Current Symbol
NASDAQ:PCLA
CIK
2018462
Web
N/A
Fax
N/A
Employees
53
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
$3.64 million
Price / Sales
0.05
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$82.71 per share
Price / Book
0.06

Miscellaneous

Outstanding Shares
40,000
Free Float
N/A
Market Cap
$194.80 thousand
Optionable
N/A
Beta
11.16
7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

This page (NASDAQ:PCLA) was last updated on 8/5/2026 by MarketBeat.com Staff.
From Our Partners